Sentinel and Phase IV: A Dilemma For FDA and Industry
This article was originally published in RPM Report
FDA and industry are both interesting in tapping into Sentinel as an alternative to traditional Phase IV studies. But how can FDA require use of the new capability without having to pay for it?
You may also be interested in...
The transition away from spontaneous adverse event reporting systems to real-time active surveillance is under way, but far from complete. Alan Goldhammer, the former head of regulatory affairs at the Pharmaceutical Research & Manufacturers of America trade association, surveys the landscape of active surveillance activities.
The Reagan-Udall Foundation is an early priority for FDA in implementing the landmark legislation enacted by Congress in 2007. It is also a lightning road for criticism from Congress about the agency's relationship with regulated industry. We asked foundation chairman Mark McClellan for a status report.
The Reagan-Udall Foundation is the one piece of the FDA drug safety law enacted in 2007 that both FDA and industry are excited about. Congressional appropriators, however, have serious concerns. The stakes are higher than they seem: in the short run, the Critical Path and active surveillance systems may depend on the foundation. In the long run, the question is whether industry has any say in the evolution of regulation.